N-(1H-indol-6-yl)-6,7-dimethoxyquinazolin-4-amine | 159768-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(1H-indol-6-yl)-6,7-dimethoxyquinazolin-4-amine
• CAS: 159768-23-7
• 化学式: C₁₈H₁₆N₄O₂
• 分子量: 320.351
• InChiKey: OGFPKVVNBFUOLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  72.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-氨基吲哚 、 4-氯-6,7-二甲氧基喹唑啉 以 乙腈 为溶剂， 反应 1.0h， 生成 N-(1H-indol-6-yl)-6,7-dimethoxyquinazolin-4-amine
  参考文献：
  名称：

  Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position

  摘要：

  We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics proved challenging. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.03.100

文献信息

• EP0602851A1
  申请人：——

  公开号：EP0602851A1

  公开（公告）日：1994-06-22
• Quinazoline derivatives
  申请人：ZENECA LIMITED

  公开号：EP0602851B1

  公开（公告）日：1996-10-09
• US5580870A
  申请人：——

  公开号：US5580870A

  公开（公告）日：1996-12-03
• Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
  作者：Allan M. Jordan、Habiba Begum、Emma Fairweather、Samantha Fritzl、Kristin Goldberg、Gemma V. Hopkins、Niall M. Hamilton、Amanda J. Lyons、H. Nikki March、Rebecca Newton、Helen F. Small、Swamy Vishwanath、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1016/j.bmcl.2016.03.100

  日期：2016.6

  We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics proved challenging. (C) 2016 Elsevier Ltd. All rights reserved.